All Companies

VRTXCongressional Stock Trades

Vertex Pharmaceuticals Inc

Pharmaceutical Preparations

Congressional stock trades in Vertex Pharmaceuticals Inc (VRTX) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.

Total Trades

10

Politicians Trading

4

Last Traded

Aug 26, 2026

Trading History

PoliticianNotifiedTradedTypeAmountChange
David TaylorRSep 5, 2026Aug 26, 2026Sell$1,001 - $15,000-7.12%
David TaylorRFeb 2, 2026Jan 29, 2026Sell$1,001 - $15,000+6.87%
David TaylorRSep 2, 2025Aug 7, 2025Buy$1,001 - $15,000+35.33%
Lisa C. McClainRAug 13, 2025Jun 11, 2025Sell$1,001 - $15,000+12.36%
Lisa C. McClainRAug 13, 2025Jun 10, 2025Sell$1,001 - $15,000+12.58%
Jefferson ShreveRJun 22, 2025May 12, 2025Sell$15,001 - $50,000+15.70%
Byron DonaldsRApr 14, 2025Mar 20, 2025Sell$1,001 - $15,000-0.36%
Byron DonaldsRApr 14, 2025Mar 20, 2025Sell$1,001 - $15,000-0.36%
Jefferson ShreveRApr 11, 2025Mar 13, 2025Buy$15,001 - $50,000+1.08%
Jefferson ShreveRMar 9, 2025Feb 24, 2025Buy$15,001 - $50,000+5.54%

Price History

About Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.